Plasma EGFR mutation detection associated with survival outcomes in advanced-stage lung cancer

Clinical Lung Cancer

Volumn 16, Issue 6, 2015, Pages 507-513

  Lam, David C L ^a   Tam, Terence C C ^a   Lau, Kenneth M K ^a   Wong, Wai Mui ^a   Hui, Christopher K M ^a   Lam, Jamie C M ^a   Wang, Julie K L ^a   Lui, MacY M S ^a   Ho, James C M ^a   Ip, Mary S M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

EGFR mutation; Lung adenocarcinoma; Plasma DNA; Prognosis; Survival outcomes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GENOMIC DNA; PEPTIDE NUCLEIC ACID; EGFR PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PEPTIDE NUCLEIC ACID LOCKED NUCLEIC ACID POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; ADENOCARCINOMA; AGED; BLOOD; CANCER STAGING; DNA MUTATIONAL ANALYSIS; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS;

ADENOCARCINOMA; AGED; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 84944353329     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.06.003     Document Type: Article

References (20)

1. Y. Shi, J.S. Au, S. Thongprasert, and et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) J Thorac Oncol 9 2014 154 162
2. H. Bai, L. Mao, H.S. Wang, and et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer J Clin Oncol 27 2009 2653 2659
3. B. Abedi-Ardekani, N.A. Dar, M.M. Mir, and et al. Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia BMC Cancer 12 2012 602
4. Y. Kuang, A. Rogers, B.Y. Yeap, and et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small-cell lung cancer Clin Cancer Res 15 2009 2630 2636
5. H. Kimura, K. Kasahara, K. Shibata, and et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small-cell lung cancer J Thorac Oncol 1 2006 260 267
6. H.R. Kim, S.Y. Lee, D.S. Hyun, and et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping J Exp Clin Cancer Res 32 2013 50
7. M. Brevet, M.L. Johnson, C.G. Azzoli, and M. Ladanyi Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors Lung Cancer 73 2011 96 102
8. K. Taniguchi, J. Uchida, K. Nishino, and et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas Clin Cancer Res 17 2011 7808 7815
9. G.R. Oxnard, C.P. Paweletz, Y. Kuang, and et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA Clin Cancer Res 20 2014 1698 1705
10. T.K. Yung, K.C. Chan, T.S. Mok, J. Tong, K.F. To, and Y.M. Lo Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small-cell lung cancer patients Clin Cancer Res 15 2009 2076 2084
11. Y. Kukita, J. Uchida, S. Oba, and et al. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data PLoS One 8 2013 e81468
12. P.C. Mack, W.S. Holland, R.A. Burich, and et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small-cell lung cancer J Thorac Oncol 4 2009 1466 1472
13. X. Liu, Y. Lu, G. Zhu, and et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small-cell lung cancer: comparison of methodologies J Clin Pathol 66 2013 1065 1069
14. G. Jian, Z. Songwen, Z. Ling, and et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small-cell lung cancer J Cancer Res Clin Oncol 136 2010 1341 1347
15. I. Yam, D.C. Lam, K. Chan, and et al. EGFR array: uses in the detection of plasma EGFR mutations in non-small-cell lung cancer patients J Thorac Oncol 7 2012 1131 1140
16. H. Kimura, M. Suminoe, K. Kasahara, and et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) Br J Cancer 97 2007 778 784
17. G.R. Oxnard, V.A. Miller, M.E. Robson, and et al. Screening for germline EGFR T790M mutations through lung cancer genotyping J Thorac Oncol 7 2012 1049 1052
18. N. Girard, C. Deshpande, C. Lau, and et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases Am J Surg Pathol 33 2009 1752 1764
19. Y.J. Lee, K.A. Yoon, J.Y. Han, and et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy Clin Cancer Res 17 2011 5179 5187
20. K. Goto, Y. Ichinose, Y. Ohe, and et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small-cell lung cancer J Thorac Oncol 7 2012 115 121